Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
06. Januar 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate
09. Dezember 2019 07:00 ET
|
Precision Biosciences
-PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%)...
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors
13. November 2019 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
12. November 2019 07:15 ET
|
Precision Biosciences
DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
06. November 2019 09:01 ET
|
Precision Biosciences
-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia- ...
Precision BioSciences to Report Third Quarter 2019 Financial Results and Present at Upcoming Investor Conferences in November
30. Oktober 2019 06:30 ET
|
Precision Biosciences
DURHAM, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations
30. September 2019 06:30 ET
|
Precision Biosciences
DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...
Precision BioSciences to Present at Upcoming Industry and Investor Conferences
26. September 2019 06:30 ET
|
Precision Biosciences
DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer
23. September 2019 06:30 ET
|
Precision Biosciences
DURHAM, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy
16. September 2019 06:30 ET
|
Precision Biosciences
Phase 1/2a Clinical Trial of Off-The-Shelf Anti-CD20 CAR T Therapy Candidate in Patients with NHL, CLL, and SLL Expected to Begin in Fourth Quarter 2019PBCAR20A has Received Orphan Drug Designation...